Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) has announced it will release its second quarter financial results and provide a corporate update on July 29, 2024. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day. Participants must register in advance to receive a dial-in number and unique access PIN. A listen-only webcast will also be available. A replay of the call will be accessible on the Investors / Events section of Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre e fornirà un aggiornamento aziendale il 29 luglio 2024. L'azienda ospiterà una conference call alle 17:00 ora orientale (14:00 ora del Pacifico) nello stesso giorno. I partecipanti devono registrarsi in anticipo per ricevere un numero di accesso e un PIN unico. Sarà disponibile anche un webcast in sola ascolto. La registrazione della chiamata sarà accessibile nella sezione Investitori / Eventi di Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) ha anunciado que publicará sus resultados financieros del segundo trimestre y proporcionará una actualización corporativa el 29 de julio de 2024. La compañía llevará a cabo una llamada de conferencia a las 5:00 p.m. hora del este (2:00 p.m. hora del pacífico) el mismo día. Los participantes deben registrarse con anticipación para recibir un número de marcación y un PIN de acceso único. También habrá un webcast solo de escucha disponible. Una repetición de la llamada estará accesible en la sección de Inversores / Eventos de Corcept.com.
Corcept Therapeutics (NASDAQ: CORT)는 2024년 7월 29일에 2분기 재무 결과를 발표하고 기업 업데이트를 제공할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시(오후 5시, 태평양 표준시 오후 2시)에 컨퍼런스 콜을 진행합니다. 참가자는 사전 등록을 해야 전화 접속 번호와 고유 접근 PIN을 받을 수 있습니다. 청취 전용 웹캐스트도 제공될 예정입니다. 콜의 재생은 Corcept.com의 투자자 / 이벤트 섹션에서 이용 가능할 것입니다.
Corcept Therapeutics (NASDAQ: CORT) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre et fournira une mise à jour d'entreprise le 29 juillet 2024. L'entreprise organisera une conférence téléphonique à 17h00, heure de l'Est (14h00, heure du Pacifique) le même jour. Les participants doivent s'inscrire à l'avance pour recevoir un numéro d'appel et un code d'accès unique. Un webinaire en écoute seule sera également disponible. Un enregistrement de l'appel sera accessible dans la section Investisseurs / Événements de Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) hat angekündigt, dass es am 29. Juli 2024 seine Finanzergebnisse für das zweite Quartal veröffentlichen und ein Unternehmensupdate bereitstellen wird. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time (14:00 Uhr Pacific Time) eine Konferenzschaltung veranstalten. Teilnehmer müssen sich im Voraus registrieren, um eine Einwahlnummer und eine einzigartige Zugangs-PIN zu erhalten. Ein nur Anhören-Webcast wird ebenfalls verfügbar sein. Eine Wiederholung des Anrufs wird im Bereich Investoren / Veranstaltungen auf Corcept.com zugänglich sein.
- None.
- None.
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of Corcept.com.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit Corcept.com.
CONTACT:
Investor inquiries:
ir@corcept.com
Media inquiries:
communications@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics (CORT) release its Q2 2024 financial results?
What time is Corcept Therapeutics' (CORT) Q2 2024 earnings call scheduled for?
How can investors participate in Corcept Therapeutics' (CORT) Q2 2024 earnings call?
Where can I find a replay of Corcept Therapeutics' (CORT) Q2 2024 earnings call?
